Document is current

Article History

Received: 4 February 2025

Accepted: 28 April 2025

First Online: 3 May 2025

Declarations

:

: This study does not contain individual patient data. In accordance with the ethics committee of the Ludwig-Maximilians-University of Munich this work is not subject to review.

: The authors declare no conflicts of interest – financial or otherwise – that may directly or indirectly influence the content of the manuscript submitted. Adrien Holzgreve is funded by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) – 545058105. He reports compensation for scientific consulting by ABX advanced biochemical compounds outside the submitted work. CL reports prior consulting activities for Blue Earth Diagnostics Ltd. (Oxford, UK) and Novartis outside the submitted work. Matthias Miederer reports compensation for scientific consulting by Novartis, Roche, Telix and Veraxa outside of the submitted work. Robert Seifert has received research/travel support from Boehringer Ingelheim Funds and the Else Kröner-Fresenius-Stiftung. Wolfgang P. Fendler reports fees from SOFIE Bioscience (research funding), Janssen (consultant, speaker), Calyx (consultant, image review), Bayer (consultant, speaker, research funding), Novartis (speaker, consultant), Telix (speaker), GE Healthcare (speaker, consultant), Eczacıbaşı Monrol (speaker), Abx (speaker), Amgen (speaker), Urotrials (speaker) outside of the submitted work.